These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9431325)

  • 1. [The value of mycophenolate mofetil in kidney transplantation. Joint Symposium of the Dutch Society of Nephrology, the German Society of Nephrology and the German Working Group for Clinical Nephrology. Aachen, 8 September 1997].
    Dtsch Med Wochenschr; 1997 Nov; 122(47 Suppl):1-6. PubMed ID: 9431325
    [No Abstract]   [Full Text] [Related]  

  • 2. [Initial experience with mycophenolate mofetil (RS 61443) after kidney transplantation].
    Friedrich J; Erhard J
    Zentralbl Chir; 1994; 119(1):48-9. PubMed ID: 8147160
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Rinsho; 2005 May; 63 Suppl 5():684-91. PubMed ID: 15954430
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of mycophenolate mofetil (Cellcept) in renal transplantation.
    Vanrenterghem Y
    Contrib Nephrol; 1998; 124():64-9; discussion 69-75. PubMed ID: 9761975
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylactic effect of mycophenolate mofetil on early outcomes of living donor kidney transplantation.
    Samadzadeh B; Alemi M; Heidarnejadiyan J; Torkamanasadi F
    Iran J Kidney Dis; 2012 Jan; 6(1):63-8. PubMed ID: 22218122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on mycophenolate mofetil.
    Goldstein SL
    Pediatr Infect Dis J; 2000 Jan; 19(1):73-5. PubMed ID: 10643854
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
    Meier-Kriesche HU
    Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
    Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
    Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients.
    Sureshkumar KK; Nghiem DD
    Transplantation; 2003 Jul; 76(2):441-2. PubMed ID: 12883215
    [No Abstract]   [Full Text] [Related]  

  • 11. Trough blood concentrations in long-term treatment with mycophenolate mofetil.
    Sanquer S; Breil M; Baron C; Dahmane D; Astier A; Lang P
    Lancet; 1998 May; 351(9115):1557. PubMed ID: 10326544
    [No Abstract]   [Full Text] [Related]  

  • 12. Tacrolimus dosing in mycophenolate-treated patients--can we get away with less?
    de Fijter JW
    Transplantation; 2011 Jul; 92(1):10-1. PubMed ID: 21654351
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants].
    van Gelder T; Gregoor PJ; Hené RJ; De Sévaux RG; Hilbrands LB
    Ned Tijdschr Geneeskd; 1998 Jul; 142(27):1550-4. PubMed ID: 9763828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation.
    Gritsch HA; Egidi MF; Sugitani A; Jordan ML; Vivas CA; Shapiro R; Scantlebury VP; Randhawa PS; Corry RJ
    Transplant Proc; 1998 Mar; 30(2):526. PubMed ID: 9532161
    [No Abstract]   [Full Text] [Related]  

  • 15. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is mycophenolate mofetil better than azathioprine in organ transplantation?
    Ruggenenti P; Remuzzi G
    Transplantation; 2006 Nov; 82(9):1242-3. PubMed ID: 17102781
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression with mycophenolic acid: one size does not fit all.
    Bennett WM
    J Am Soc Nephrol; 2003 Sep; 14(9):2414-6. PubMed ID: 12937322
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of severe acute vascular rejection in a renal allograft with mycophenolate mofetil and high dose steroids.
    Lafferty ME; Lang S; McGregor E; Henderson IS; Jones MC
    Scott Med J; 1997 Jun; 42(3):79-80. PubMed ID: 9351121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.